Augmentin (Beecham Laboratories, Bristol, Tenn.), a combination drug consisting of two parts amoxicillin to one part clavulanic acid and a potent betalactamase inhibitor, was evaluated in vitro in comparison with ampicillin or amoxicillin or both for its inhibitory and bactericidal activities against selected clinical isolates. Regression analysis was performed and tentative disk diffusion susceptibility breakpoints were determined. A multicenter performance study of the disk diffusion test was conducted with three quality control organisms to determine tentative quality control limits. All methicillin-susceptible staphylococci and Haemophilus influenzae isolates were susceptible to Augmentin, although the minimal inhibitory concentrations for beta-lactamase-producing strains of both groups were, on the average, fourfold higher than those for enzyme-negative strains. Among the Enterobacteriaceae, Augmentin exhibited significantly greater activity than did ampicillin against Klebsiella pneumoniae, Citrobacter diversus, Proteus vulgaris, and about one-third of the Escherichia coli strains tested.
Augmentin (Beecham Laboratories, Bristol, Tenn.), a combination drug consisting of two parts amoxicillin to one part clavulanic acid and a potent betalactamase inhibitor, was evaluated in vitro in comparison with ampicillin or amoxicillin or both for its inhibitory and bactericidal activities against selected clinical isolates. Regression analysis was performed and tentative disk diffusion susceptibility breakpoints were determined. A multicenter performance study of the disk diffusion test was conducted with three quality control organisms to determine tentative quality control limits. All methicillin-susceptible staphylococci and Haemophilus influenzae isolates were susceptible to Augmentin, although the minimal inhibitory concentrations for beta-lactamase-producing strains of both groups were, on the average, fourfold higher than those for enzyme-negative strains. Among the Enterobacteriaceae, Augmentin exhibited significantly greater activity than did ampicillin against Klebsiella pneumoniae, Citrobacter diversus, Proteus vulgaris, and about one-third of the Escherichia coli strains tested. Bactericidal activity usually occurred at the minimal inhibitory concentration. There was a slight inoculum concentration effect on the Augmentin minimal inhibitory concentrations. On the basis of regression and error rate-bounded analyses, the suggested interpretive disk diffusion susceptibility breakpoints for Augmentin are: susceptible, >18 mm; resistant, <13 mm (gram-negative bacilli); and susceptible, .20 mm (staphylococci and H. influenzae). The use of a betalactamase-producing organism, such as E. coli Beecham 1532, is recommended for quality assurance of Augmentin susceptibility testing.
The increasing prevalence of clinical bacteria producing plasmid-mediated beta-lactamases has progressively restricted the usefulness of beta-lactamase-susceptible penicillins such as ampicillin and amoxicillin. When either of these drugs is combined with a potent beta-lactamase inhibitor such as clavulanic acid, the penam is protected from the beta-lactamase and is thus free to exert its normal antimicrobial activity (4, 8, 13, 20) . Clavulanic acid inhibits beta-lactamases by virtue of its strong affinity for and irreversible binding to certain beta-lactamases, especially plasmid-mediated enzymes (19) . Various combinations of beta-lactam antibiotics with clavulanic acid have been shown to exhibit synergism against beta-lactamase-producing bacteria (4, 8, 13, 20) . Noteworthy among these bacteria are beta-lactamase-producing staphylococci, Haemophilus itfluenzae, Neisseria gonorrhoeae, and several Enterobacteriaceae spp. The combination of amoxicillin plus clavulanic acid at a 2-to-1 ratio is known as Augmentin (Beecham Laboratories, Bristol, Tenn.). The potential usefulness of this compound has been demonstrated in several preliminary clinical studies (3, 7, 9, 12, 18) .
The purposes of this study were to (i) assess the susceptibility of a wide variety of clinical bacterial isolates to Augmentin by both broth microdilution and disk diffusion methods, (ii) evaluate the bactericidal activity of Augmentin, (iii) determine the effect of inoculum size on the activity of this drug, (iv) perform a regression analysis on the susceptibility data from which tentative susceptible and resistant breakpoints would be derived, and (v) evaluate the performance of standard quality control (QC) organisms with this drug. Table 3 ). For ceptible to Augmentin. Beta-lactamase-producing staphylococci required 1-0.5 to 8-4 ,ug of Augmentin per ml for inhibition of growth, and enterococci were generally inhibited by 1-0.5 ,ug/ ml. All others were inhibited by substantially lower concentrations. All beta-lactamase-producing H. influenzae strains were resistant to ampicillin and were inhibited by Augmentin, but the MICs were two to four times higher than those for ampicillin-susceptible strains. Neisseria meningitidis was highly susceptible to Augmentin and to each of its components individually.
There was a moderate effect of inoculum concentration on Augmentin MICs (Fig. 1), Augmentin at c2 gI.g/ml. Augmentin MICs for beta-lactamase producers ranged from 0.5-0.25 to 2-1 ,ug/ml, whereas those for ampicillin-susceptible strains ranged from 0.06-0.03 to 0.5-0.25 ,ug/ml. The ampicillin zone diameter susceptible breakpoint for H. influenzae of .20 mm (4) correctly separated beta-lactamase producers from enzyme-deficient strains. When the same >20-mm susceptible breakpoint was utilized for Augmentin, the beta-lactamase-producing strains fell in the susceptible category.
All staphylococci were susceptible (MIC, Table 3 .
DISCUSSION
Among the Enterobacteriaceae, the synergistic effect of the amoxicillin-clavulanic acid combination that constitutes Augmentin was most apparent with K. pneumoniae, C. diversus, and P. vulgaris. Whereas some E. coli and E. agglomerans strains responded in a similar fashion, many did not, and showed no greater response to Augmentin than to ampicillin. The other Enterobacteriaceae and Pseudomonas spp. were generally resistant to both ampicillin and Augmentin at the concentrations tested. These findings are consistent with those of previous reports (9, 12) and also correlate with the recognized inhibitory activity of clavulanic acid again$t Richmond-Sykes types II, III, IV, and V beta-lactamases but not against type I enzymes (17). Because the P. mirabilis isolates in this series were all non-beta-lactamas, producing and hence susceptible to ampicillin, we were unable to demonstrate the Augmentin synergy described by others against this species (4, 8, 13, 20) .
Since the pharmacokinetics of amoxicillin in Augmentin are essentially the same as those of amoxicillin alone (1), the MIC correlate (c8 eig/ml) for the disk diffusion susceptible breakpoint of ampicillin, as recommended by the NCCLS (16) , was chosen for the MIC susceptible breakpoint for the amoxicillin component of Augmentin for gram-negative bacteria. Based on susceptible and resistant Augmentin breakpoints of c8-4 and -32-16 gj.g/ml, respectively, the corresponding zone diameter breakpoints calculated by regression and error rate-bounded methods are .18 and -13 mm, with an indeterminant range of 14 to 17 mm. The very-major and major error rates were each less than 1% with these breakpoints, and the minor-error rate was only 4.1%. That the zone diameter breakpoint for Augmentin is greater than that for ampicillin is a reflection of the 20- (5), P.fluorescens (7), P. maltophilia (4), P. putida (6) , and P. stutzeri (12) .
cate that many of the infections caused by betalactatnase-producing Enterobacteriaceae strains respond when treated with Augmentin (9, 12, 17, 21 Our data on H. influenzae supports that of others (2, 18) in that beta-lactamase-producing strains are both resistant to ampicillin and susceptible to Augmentin. Although the Augmentin MICs for beta-lactamase-producing strains were, on the average, fourfold higher than those for non-beta-lItamase producers, the MICs were all <2-1 FLg/ml and thus equivalent to the 2-pg/ml susceptible breakpoint for ampicillin (10 
